^
    15d
    ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (clinicaltrials.gov)
    P3, N=402, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Mar 2030 --> May 2031 | Trial primary completion date: Jun 2027 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    20d
    Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014-2025). (PubMed, Clin Exp Med)
    Thematic analysis identified research hotspots across multiple dimensions, including 5q deletion, trisomy 8, germline predisposition, TP53 mutation, clonal hematopoiesis, inflammation, venetoclax, luspatercept, targeted therapy, immunotherapy, pediatric population, VEXAS syndrome, IPSS-R, relapse, prognosis, overall survival, and artificial intelligence. Future advances are expected to rely on multi-ethnic cohort building, mechanism exploration, combined treatment regimen optimization and novel drug development. Strengthening multidisciplinary collaboration is anticipated to facilitate clinical translation and foster more precise, equitable and clinically practical management of MDS globally.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Reblozyl (luspatercept-aamt)
    22d
    Luspatercept for CIA in AML (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Guangdong Second Provincial General Hospital
    New P1/2 trial
    |
    Reblozyl (luspatercept-aamt)
    23d
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2026 --> Jun 2028 | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    1m
    MAXILUS: A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (clinicaltrials.gov)
    P3, N=106, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2027 --> Sep 2027
    Trial completion date
    |
    Reblozyl (luspatercept-aamt)
    1m
    Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    1m
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 10
    Enrollment closed • Enrollment change
    |
    Reblozyl (luspatercept-aamt)
    1m
    A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China (clinicaltrials.gov)
    P=N/A, N=88, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    2ms
    A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions (clinicaltrials.gov)
    P2, N=30, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=70 --> 6
    Enrollment closed • Enrollment change
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    SF3B1 mutation • SRSF2 mutation
    |
    Reblozyl (luspatercept-aamt)